06/02/2026 Sodium zirconium cyclosilicate for treating hyperkalaemia
The Ministry of Health’s Drug Advisory Committee has recommended:
- Sodium zirconium cyclosilicate 5 g powder for oral suspension for the treatment of chronic hyperkalaemia in patients with chronic kidney disease Stage 3b to 5 (nondialysis dependent):
- who have experienced at least 2 episodes of hyperkalaemia (defined as serum potassium levels of at least 5.5 mmol/L) in the past 12 months, and
- who are receiving treatment with a renin-angiotensin-aldosterone system (RAAS) inhibitor, or who are indicated for treatment with a RAAS inhibitor but unable to tolerate it due to hyperkalaemia.
Funding status
RSodium zirconium cyclosilicate 5 g powder for oral suspension is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 April 2026.
NRMAF assistance does not apply to sodium zirconium cyclosilicate 10 g powder for oral suspension.